Background {#Sec1}
==========

In recent years, colistin has been considered as an effective therapeutic option for the rapid increasing of multidrug-resistant (MDR) gram-negative pathogens \[[@CR1], [@CR2]\]. However, the prevalence of the mobile colistin resistance gene (*mcr*-1) in animals and human beings worldwide has challenged this viewpoint \[[@CR3], [@CR4]\]. Resistance to polymyxins is mainly caused by the modification to bacterial outer membrane, which was usually considered as chromosomally mediated resistance \[[@CR5], [@CR6]\].

Since it was initially found, plasmid-mediated *mcr*-1 has been detected widely \[[@CR3], [@CR7]\]. Nowadays, *mcr*-1-producing bacteria have been reported in many regions in China \[[@CR4], [@CR8]\]. *Mcr*-1 was firstly found in *Escherichia coli* (*E. coli*), and now it has been spreading to other *Enterobacteriaceae* \[[@CR9]\]. Several reports showed that the *mcr*-1 gene could coexist with other resistance genes (such as CRE/ESBL) in *E. coli* and *Klebsiella pneumoniae*, which probably lead to the emergence pan-drug resistant and increase the difficulty of treatment \[[@CR8], [@CR10]\]. Therefore, the emergence and spread of *mcr*-1 gene among human beings should be given close attention. The aim of this study was to evaluate the prevalence of *mcr*-1 in *E. coli* clinical isolates in a Chinese teaching hospital, and to investigate the molecular characteristics of these strains.

Methods {#Sec2}
=======

Bacterial strains {#Sec3}
-----------------

A total of 700 *E. coli* clinical isolates were collected from the clinical laboratory of Fujian Medical University Union Hospital (Fuzhou, Fujian province, China) from August 2014 to August 2015. It is a 2200-bed tertiary care teaching hospital with approximately 95,000 hospital admissions per year, located in southeastern China. All isolates were identified by GNI card of the Vitek system (BioMèrieux, Missouri, France).

Antibiotic susceptibility testing {#Sec4}
---------------------------------

Antimicrobial susceptibility testing was performed using the AST-GN16 of Vitek-2 Compact system (Bio Mérieux, France). The antimicrobial agents tested included: tigecycline (glycycline); ertapenem and imipenem (carbapenems); cefazolin; cefoxitin; cefepime, and cefotaxime (cephalosporins); aztreonam (monobactam); amikacin and gentamicin (aminoglycosides); ciprofloxacin and levofloxacin (quinolone); piperacillin/tazobactam; trimethoprim/sulfamethoxazole. The results were interpreted by the Clinical and Laboratory Standards Institute (CLSI) \[[@CR11]\]. The MIC of colistin was determined using agar dilution method, and the result was interpreted according to European Committee On Antimicrobial Susceptibility Testing (EUCAST) guidelines \[[@CR12]\]. *E. coli* ATCC 25922 was used as a quality control.

DNA extraction {#Sec5}
--------------

Several colonies were suspended in 50 µl of sterile distilled water for preparing genomic DNA of the isolates, and then the bacterial suspension was heated at 100 °C for 10 min as described previously \[[@CR13]\].

MCR-1 detection {#Sec6}
---------------

*mcr*-*1* gene was screened in *E. coli* clinical isolates by PCR using primers as previously described \[[@CR4]\]. All of the PCR products were sequenced and then compared with known sequences listed in the GenBank (<http://www.ncbi.nlm.nih.gov/blast/>).

Detection of virulence factor genes {#Sec7}
-----------------------------------

Twenty six virulence factors (VFs) genes associated with extraintestinal virulence \[[@CR14], [@CR15]\] were detected using a multiplex PCR method as previously described \[[@CR15]\]. These genes were as follows: adhesions (*pap*AH, *pap*EF, *pap*C, *pap*G allele I, *pap*G II/III, *pap*G allele II, *sfa/foc*DE, *afa/dra*BC, *fim*H, *gaf*D, *sfa*S, *foc*G and *nfa*E), toxins (*hly*A, *cnf*1 and *cdt*B), siderophores (*fyu*A and *iut*A), protections and invasions (*kps*MTII, *kps*MTIII, *tra*T, *cva*C, kpsMT and K1/K5), miscellaneous (*rfc* and PAI). The PCR products were sequenced and then compared with known sequences listed in the GenBank (<http://www.ncbi.nlm.nih.gov/blast/>).

Phylogenetic analysis {#Sec8}
---------------------

The phylogenetic groups (A, B1, B2, and D) of *mcr*-1 producing *E. coli* isolates were identified by a triplex PCR as previously described \[[@CR16]\].

Multi-locus sequence typing (MLST) {#Sec9}
----------------------------------

*Mcr*-1 positive strains were analyzed by multilocus sequence typing (MLST), which was based on 7 standard housekeeping genes (*adk, fumC, gyrB, icd, mdh, purA, recA*) (<http://mlst.ucc.ie/mlst/mlst/dbs/Ecoli>) \[[@CR17]\].

DNA fingerprinting {#Sec10}
------------------

Enterobacterial Repetitive Intergenic Consensus Sequences PCR (ERIC-PCR) was applied to typing *mcr*-1 producing *E. coli* isolates with the primers ERIC-1 and ERIC-2 \[[@CR18]\]. DNA fingerprints were compared by visual inspection, ERIC profiles were regarded as different if there were different bands on visual inspection \[[@CR19]\].

Results and discussion {#Sec11}
======================

In this study, four isolates (0.6%) were confirmed to carry *mcr*-1 gene, which is lower than previous study \[[@CR4]\]. The age of the patients ranged between 38 and 80 years. These *mcr*-1 producing strains were isolated from two different wards (Table [1](#Tab1){ref-type="table"}). Two strains were isolated from the same patient. The clinical data of patients with *mcr*-1 positive *E. coli* infection were shown in Table [2](#Tab2){ref-type="table"}.Table 1Main characteristics of the *mcr*-1 *E. coli*IsolatesDataWardSpecimenPhylogenetic groupsMLSTERIC patternVFsAntibiotic resistanceE3212014.8Colorectal surgeryDrainage-fluidB1ST1561*tra*T, *iut*ACOL, CFZ, FOX, CIP, LVX, SXT, TGCE6842015.1Colorectal surgerySecretionB1ST1562*fim*H, *tra*T, *iut*ACOL, CFZ, CTX, FEP, ATM, GEN, CIP, LVX, SXTE9212015.4Hepatobiliary surgerySecretionAST1673*fyu*A, *tra*T, *iut*ACOL, CFZ, CTX, ATM, GEN, CIP, LVX, SXTE10052015.5Hepatobiliary surgeryDrainage-fluidAST1673*fyu*A, *cva*C, *tra*T, *iut*ACOL, CFZ, CTX, ATM, GEN, CIP, LVX, SXT*CFZ* cefazolin, *FOX* cefoxitin, *CTX* cefotaxime, *FEP* cefepime, *TZP* piperacillin/tazobactam, *ATM* aztreonam, *IPM* imipenem, *ETP* ertapenem, *AMK* amikacin, *GEN* gentamicin, *CIP* ciprofloxacin, *LVX* levofloxacin, *SXT* trimethoprim/sulfamethoxazole, *TIG* tigecycline, *COL* colistin, *MLST* multi-locus sequence typing, *ERIC* enterobacterial repetitive intergenic consensus, *VFs* virulence factor genes Table 2Clinical data of patients with mcr-1 positive *E. coli* infectionIsolatesPatientsGenderAge (years)Underlying diseasesLength of hospital stay (days)Treatments usedOutcomesE321Patient 1Female80Malignancy, hypertension, pulmonary tuberculosis51TZPSurvivedE684Patient 2Female57Perineal infection, hypertension37TZPSurvivedE921Patient 3Male38Hypertension, pancreatitis, diabetes26MEMSurvivedE1005Patient 3Male38Hypertension, pancreatitis, diabetes26MEMSurvived*TZP* piperacillin/tazobactam, *MEM* meropenem

*Mcr*-1 was usually found to be co-localized with other resistance genes on plasmids, such as ESBL genes and carbapenemase genes \[[@CR20]\], which might increase the emergence of pan-drug resistance. In our study, the results of antimicrobial susceptibility test showed a high drug resistance in the *mcr*-1-producing isolates. All of the *mcr*-1 positive isolates were resistance to at least 3 different kinds of antibiotics (Table [1](#Tab1){ref-type="table"}).

All four *mcr*-1 positive strains detected in our study were resistant to colistin and the MICs ranged from 4 to 16 μg/ml. It will be worrisome once *mcr*-1 coexists with other resistant genes, especially carbapenemase genes because of limited therapeutic options \[[@CR20]\]. Previous studies revealed that *mcr*-*1* co-produced with carbapenem-resistant genes in *E. coli* \[[@CR8], [@CR21]\]. Fortunately, all of them were susceptible to carbapenems (IPM and ETP), which probably indicated that no carbapenem-resistant genes coexisted with *mcr*-1. Result of ERIC-PCR (Fig. [1](#Fig1){ref-type="fig"}) showed that four *mcr*-1 positive strains were categorized into three different genotypes, one of which contained 2 strains (from the same patient). These isolates which have different patterns suggest that they were non-clonal transmission. In a previous study, two *mcr*-1 positive *E. coli* isolates from a single fowl were belonging to phylogenetic B1 and D group \[[@CR22]\]. The *mcr*-1-producing isolates in this study were belonged to phylogenetic groups A and B1, which were mainly distributed among human commensal *E. coli* isolates \[[@CR23]\]. The *mcr*-1 producing isolates were assigned by MLST to two different sequence types: ST156 and ST167 (Table [1](#Tab1){ref-type="table"}), which was similar to previous reports in other studies from China \[[@CR8], [@CR22]\]. *E. coli* ST156 has been found that it has connection with different ESBL genes \[[@CR24], [@CR25]\]. ST167 was belonged to ST10 complex and regarded as prevalent ST among ESBL-producing *E. coli* from human and animal sources \[[@CR26]\]. In addition, *E. coli* ST167 was reported to be closely related to *bla* ~NDM~, which needed closely concern of spreading \[[@CR27]\]. The similar molecular characterizations illustrated that *mcr*-1 positive isolates detected from the same department in our study were clonally related.Fig. 1ERIC-PCR products from four mcr-1 positive isolates. *M* mark, *lane 1* E321, *lane 2* E684, *lane 3* E921, *lane 4* E1005

VFs in *E. coli* were associated with colonization, bacterial fitness and virulence \[[@CR28]\]. VFs include five main groups: (1) adhesions; (2) toxins; (3) siderophores; (4) capsule production and (5) protections and invasions. Clinical *E. coli* strains often carry multiple VFs, and isolates belonging to groups A and B1 often have less VFs than those belonging to phylogroups B2 and D \[[@CR28]\]. To the best of our knowledge, there is no study concerning about VFs in *mcr*-*1* producing *E. coli*. In our study, *mcr*-*1* producing isolates contained less than 4 different VFs (Table [1](#Tab1){ref-type="table"}). Only five different kinds of VFs had been detected in our *mcr*-*1* positive isolates, which included *fim*H, *fyu*A, *tra*T, *iut*A and *cva*C. *fim*H is one of the most commonly VFs present in *E. coli*, which encodes the adhesion subunit of type 1 fimbriae and related to colonization \[[@CR15]\]. Lee et al. reported that *fyu*A, *tra*T, and *iut*A were found to be independent predictors for pathogenicity. Meanwhile, *tra*T and *iut*A were thought to be closely related to ESBL genes \[[@CR29]\]. Pitout et al. found that *cva*C was only present in non-CTX-M-producing isolates \[[@CR30]\]. Previous reports suggested that antibiotic resistance has negative association with virulence factors \[[@CR31]\], which could be interpreted by the loss of VFs associated with mutation to resistance \[[@CR32]\].

It is noteworthy that two *mcr*-1 positive *E. coli* strains were isolated from the same patient but at different time (Table [1](#Tab1){ref-type="table"}). Results of MLST and ERIC-PCR revealed that these isolates had identical genetic background. Result of antimicrobial susceptibility test showed that they had similar antibiograms. We speculate that the two isolates probably originated from a same source.

In conclusion, we have revealed a low prevalence of *mcr*-*1* in *E. coli* clinical isolates in a Chinese teaching hospital, and presented detailed molecular characteristics of these isolates. The presence of *mcr*-1 in *E. coli* clinical isolates suggests that it will pose a threat to public healthcare. Effective infection control measures are urgently needed to take to control the transmission of *mcr*-1 gene.
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